anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to methods and compositions for reducing immune rejection, for example, transplant- or autoimmune disorder-related immune rejection. The present invention also relates to methods and compositions for monitoring transplant acceptance and for monitoring an autoimmune disorder in a subject mammal. The present invention still further relates to methods for identifying compounds that can reduce immune rejection. The present invention is based, in part, on the discovery, demonstrated herein, that immune rejection can be monitored by determining the amount of particular members of the Jak/Stat signal transduction pathway present within an affected tissue (that is, a transplant cell, tissue, organ, or organ system, or a cell, tissue, organ, or organ system that is, or is suspected of, being affected by an autoimmune disorder). The present invention is further based, in part, on the discovery, demonstrated herein, that immune rejection can be reduced and tolerance can be induced by modulating the amount of these particular members of the Jak/Stat signal transduction pathway present, expressed or active within an affected tissue. In particular, the results presented herein demonstrate that immune rejection can be monitored by determining the amount of Stat1 mRNA or protein, Stat2 mRNA or protein, Stat3 mRNA or protein, Stat4 mRNA or protein, Stat6 mRNA or protein, SOCS1 mRNA or protein, or SOCS3 mRNA or protein present, e.g., present in an affected tissue.
Following injection, drug plasma concentrations declined rapidly in a biexponential manner with distribution phase and terminal elimination phase half-lives of approximately 10 and 75 minutes, respectively. Estimates of average total body clearance varied among studies, but typical values of approximately 7 to 9 mL/min/kg (250 to 325 mL/min/m2) were observed. One study has reported that on repeat dosing of 0.5 mg/kg every 6 weeks, the clearance of melphalan decreased from 8.1 mL/min/kg after the first course, to 5.5 mL/min/kg after the third course, but did not decrease appreciably after the third course. Mean (±SD) peak melphalan plasma concentrations in myeloma patients given IV melphalan at doses of 10 or 20 mg/m2 were 1.2 ± 0.4 and 2.8 ± 1.9 mcg/mL, respectively.

The steady-state volume of distribution of melphalan is 0.5 L/kg. Penetration into cerebrospinal fluid (CSF) is low. The average melphalan binding to plasma proteins is highly variable (range: 53% to 92%). Serum albumin is the major binding protein, accounting for approximately 40% to 60% of the plasma protein binding, while α1-acid glycoprotein accounts for about 20% of the plasma protein binding. Approximately 30% of melphalan is (covalently) irreversibly bound to plasma proteins. Interactions with immunoglobulins have been found to be negligible.

Melphalan is eliminated from plasma primarily by chemical hydrolysis to monohydroxymelphalan and dihydroxymelphalan. Aside from these hydrolysis products, no other melphalan metabolites have been observed in humans. Although the contribution of renal elimination to melphalan clearance appears to be low, one study noted an increase in the occurrence of severe leukopenia in patients with elevated BUN after 10 weeks of therapy.
FIELD: organic chemistry, peptides. SUBSTANCE: invention relates to the synthesis of peptides showing an antialcoholic activity. Invention describes the novel tetrapeptide of the general formula (I): Trp-Nle-Asp-PheNH-CH(CH 3 ) 2 . Proposed tetrapeptide can be used as a base for development of medicinal forms showing an antialcoholic activity. The developed tetrapeptide shows an antialcoholic activity, does not produce anxiogenic effect at peripheral route of administration. EFFECT: synthesis of tetrapeptide indicated above, antialcoholic properties, decreased cost of synthesis, absence of adverse effect. 3 tbl, 3 ex
Patients admitted on this protocol will have, or be suspected of having, a Leishmania infection. The major objectives of the protocol are to diagnose and classify the Leishmania infection and to provide species-based therapy to study the natural history of the treated infection and further understand host and species characteristics that lead to resistant or relapsing disease. As part of the standard evaluation of these patients, biopsies to obtain parasite and host tissue will be obtained. The host response before and after therapy will be assessed to address broader questions related to diagnosis, disease pathogenesis, and response to therapy. Careful observations of the patients clinical and immunologic responses to therapy will be made, as well as long-term follow-up of these changes. It is anticipated that the patients will receive optimal clinical care for their infections and that the specimens collected from them will prove to be valuable reagents for the laboratory studies of the host responses unique to leishmanial infections.
BACKGROUND: Inflammation and oxidative stress play an important role in the pathophysiology of inflammatory bowel disease (IBD). This study aimed to explore the effects of copper chaperone Antioxidant-1 (Atox1) on macrophages in a mouse model of intestinal inflammation.
METHODS: A mouse model of TNBS-induced colitis was established and verified using the disease activity index. Atox1 conditional knockout mice were applied. The proportion of macrophages in colonic lamina propria mononuclear cells and ROS production were analyzed using flow cytometry. Inflammatory cytokines were measured using ELISA. Expression of macrophage M1/M2 polarization markers, p47phox, NLRP3, and Caspase-1 p20 was measured using quantitative RT-PCR and Western blotting.
RESULTS: Atox1 expression was up-regulated in colon tissues of TNBS-induced colitis mice. Macrophages isolated from TNBS-induced colitis mice showed M1 polarization and nuclear translocation of Atox1. Inhibiting copper chaperone activity decreased p47phox, ROS production, and M1 polarization induced by CuCl2 in macrophages. TNBS induced up-regulation of inflammatory cytokines, M1 polarization markers, and p47phox expression in mice, an effect which was preempted by Atox1 knockout. Inflammatory cytokines and expression of M1 polarization markers, p47phox, NLRP3, Caspase-1 p20 were also increased in macrophages isolated from TNBS-induced colitis mice. These changes were alleviated in mice with Atox1 knockout. The effects of Atox1 on macrophage polarization were mediated via the ROS-NLRP3 inflammasome pathway.
CONCLUSION: Atox1 plays a pro-inflammatory role, promotes M1 polarization of macrophages, and increases the concentrations of pro-inflammatory cytokines in intestinal tissue by regulating the ROS-NLRP3 inflammasome pathway. Atox1 is a potential therapeutic target in IBD.
Breastfeeding Counseling Based on Motivational Interviewing: An announcement was made on social media. Women who were willing to participate in the research and met the inclusion criteria were informed about the research and an appointment was made with them and they were scheduled to log in. All sessions were held with women individually and through online platforms. Motivational Interview-Based Breastfeeding Training Hypnobreastfeeding training program consists of 6 sessions and 4 parts. A total of 6 sessions were held with each woman, 3 implementation and 3 follow-ups.
PCT No. PCT/US91/02156 Sec. 371 Date Nov. 14, 1991 Sec. 102(e) Date Nov. 14, 1991 PCT Filed Mar. 29, 1991 PCT Pub. No. WO91/15250 PCT Pub. Date Oct. 17, 1991.A polymeric, amphoteric hydrogel for use in medical devices and medical devices using the hydrogel. The hydrogel has a first polymer repeating unit having a acid group and a second polymer repeating unit having a base group such that the acid groups and base groups are present in the hydrogel in amounts effective to provide a hydrogel with a strong, amphoteric, nonmobile ionic structure. For example, the hydrogel can be a copolymer of 2-acrylamido-2-methylpropane sulfonic acid and methacrylamido-propyl-trimethylammonium hydroxide. The hydrogel can be an adhesive used to adhere medical devices to the skin of a patient. It can be particularly useful in drug delivery applications such as in iontophoresis devices.
Volunteers randomized into Slow-speed strength training (SSST) will be exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength for LP and KE exercises.
PROBLEM TO BE SOLVED: To protect the surface of a curable composition multiused as a dental or surgical coating material composition and using a polymerization initiator containing boron in the molecule with a coating material layer having sufficient surface hardness. SOLUTION: This coating material composition is a coating material composition for applying the surface of a curable composition using a boron-containing polymerization initiator and comprises (A) (meth)acrylate having urethane bond in the molecule, (B) (meth)acrylate having oxyetheylene unit in the molecule, (C) a volatile compound and (D) an α-ketocarbonyl compound and contains 30-80 pts.wt. component A, 5-40 pts.wt. component B, 5-40 pts.wt. component C and 0.01-10 pts.wt. component D in 100 pts.wt. total weight of components A, B, C and D.
Normal, healthy volunteers who express interest in participation and who meet the eligibility criteria will be recruited for this study. It is anticipated that healthy volunteers will mostly consist of medical professionals. They will consist of 10 monolinguals (defined as native English speakers), 10 early bilinguals (defined as acquiring proficiency in the second language before 10 years of age), and 10 late bilinguals (defined as acquiring proficiency in the second language after 10 years of age).
It is performed by inserting a needle through the sacral hiatus to gain entrance into the sacral epidural space. Using conventional blind technique, the failure rate of caudal epidural block is high even in experienced hands. With the advent of ultrasound in guiding needle placement, the success rate of caudal epidural block has been markedly improved and could be effective in preventing complications during caudal epidural injection. After administration of a caudal block, reliable assessment of caudal block is very crucial to ascertain the success of block. The onset of caudal block is often assessed by cold stimuli and cutaneous temperature changes. Caudal block in pediatric patients is often performed under general anesthesia. Hence, testing the sensory levels by above techniques cannot be used. Also the change in the hemodynamic parameters are few other assessment methods. These methods are to be used 15-20 min after block administration, to confirm the efficacy of a caudal block. Perfusion index (PI), independent of parameters like heart rate, oxygen saturation of blood, or body temperature, measures the ratio of arterial blood flow (pulsatile flow) to venous, capillary, and tissue blood flow (non-pulsatile blood flow) and it is shown in percentage or absolute value . PI is considered as a sensitive marker to assess the efficacy of caudal block. It can detect the onset of caudal block, by increasing PI beyond the pre-induction values, which can be due to the sympathectomy induced after successful caudal administration,which increases the blood flow to the peripheral tissues.
At the conclusion of cardiopulmonary bypass, protamine administration will be undertaken at surgical request. For patients in the control group, protamine will be dosed on a 1:1 ratio according to the total dose of heparin initially required to establish a therapeutic activated clotting time (ACT) (i.e. if 30,000 IU were required prior to initiating cardiopulmonary bypass, then the protamine dose will be 300mg).
PURPOSE:To obtain a bath agent composition being mild in feeling in bathing, capable of smoothing skin after bathing, having excellent fluidity, free from trouble in production and capable of readily taking out from a vessel of bath agent by impregnating an oily liquid into powdery saccharides. CONSTITUTION:An oily liquid (e.g. soybean oil, sesame oil, olive oil, avocado oil, castor oil or palm oil) is impregnated into powdery saccharides (e.g. saccharose; maltose, lactose, glucose or xylose). Blend amount of the powdery saccharide is 30-90wt.%, preferably 50-90wt.% based on total amount of composition and blend amount is 1-25 pts.wt., preferably 5-20 pts.wt. based on 100 pts.wt. saccharide. Carbonic acid salt (e.g. NaHCO3) and organic acid (e.g. cinnamic acid or furmaric acid) are preferably blended in the bath agent composition.
BACKGROUND: Safe anesthesia is imperative for the Global Surgery agenda and Sustainable Development Goal 3. Due to a shortage of specialists in South Africa (SA), anesthetic services are often provided by nonspecialist doctors, often newly qualified and frequently without immediate supervision. The burden of disease in the developing world demands fit-for-purpose, day-one medical graduates. Although undergraduate anesthesia training is mandatory for medical students in SA, no outcomes are specified, and these are decided autonomously at each medical school. This study describes the current self-perceived anesthetic competence of medical students in SA as a needs assessment directed at achieving the goals of Global Surgery in SA and other developing countries.
METHODS: In this cross-sectional observational study, 1689 students (89% participation rate), representing all medical schools in SA, rated their self-perceived competence at graduation in 54 anesthetic-related Likert scale items in 5 themes: patient evaluation, patient preparation for anesthesia, practical skills performance, administration of anesthesia, and the management of intraoperative complications. Medical schools were divided into clusters A (≥25 days of anesthetic training) and B (<25 days). Descriptive statistics, Fisher exact test, and a mixed-effects regression model were used in the statistical analysis.
RESULTS: Students felt more prepared for history-taking and patient examination than for managing emergencies and complications. The self-perceived competence of students at cluster A schools was higher across all 54 items and all 5 themes. The same was observed for general medical skills and skills relating to maternal mortality in SA.
CONCLUSIONS: Time-on-task, capacity for repetition, and student maturity might have impacted self-efficacy and should be considered in curriculum development. Students felt less prepared for emergencies. Focused training and assessment aimed at emergency management should be considered. Students did not feel competent in general medical areas, in which anesthetists are experts, including resuscitation, fluid management, and analgesia. Anesthetists should take ownership of this training at the undergraduate level. Cesarean delivery is the most performed surgical procedure in sub-Saharan Africa. The Essential Steps in Managing Obstetric Emergencies (ESMOE) program was designed for internship training but can be introduced at undergraduate level. This study suggests that curriculum reform is required. The achievement of an agreed-upon set of standardized national undergraduate anesthetic competencies may ensure fit-for-purpose practitioners. Undergraduate and internship training should align to form part of a continuum of basic anesthetics training in SA. The findings of this study might benefit curriculum development in other regions with similar contexts.
CPP-ACP paste (GC Tooth Mousse,Gc,USA)was applied by patients once daily. 3gr,for 42 days.
The invention relates to the field of avian infectious bronchitis virus vaccines of veterinary biological products and particularly relates to an avian infectious bronchitis virus 451 strain, of which the preservation number is CGMCCNo. 8882. The avian infectious bronchitis virus 451 strain is applied to preparing avian infectious bronchitis virus vaccines. The avian infectious bronchitis virus 451 strain is relatively weak in pathogenicity to chicken and has good immunogenicity. The vaccine prepared by applying the strain is safe and reliable, not only can provide homologous attacking protection, but also can provide certain cross protection to heterogenous attacking. The morbidity and mortality of inoculated chicken flocks are remarkably reduced. The strain can be used for effectively preventing prevalence and propagation of avian infectious bronchitis and reducing the economic loss caused by the disease, and has a wide application prospect.
Participants with an eGFR \<30 mL/min/1.73 m\^2 receive a single dose of MK-7655 125 mg + PRIMAXIN® 250 mg IV in Part 1. In Part 2, participants receive an oral cocktail containing caffeine 200 mg, midazolam 2 mg, and omeprazole 40 mg.
The invention discloses application of a lactone compound derived from aspergillus aculeatus in an anti-human breast cancer drug. The compound has effect in inhibiting proliferation of human breast cancer cells. The structural formula is as follows: . Aspergillus minutissima Aspergillus gracilis IBPT-8 is cultured by fermentation to obtain a fermented product, and the compound is separated and purified from the fermented product. Experiments prove that the compound has better anti-tumor activity on human breast cancer MCF-7. Can be used for preparing human breast cancer cell proliferation inhibition drugs or antitumor drugs for research of human breast cancer.
CABLIVI increases the risk of bleeding [see Adverse Reactions (6.1)].

In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.

In the postmarketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.

The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation [see Drug Interactions (7) and Clinical Pharmacology (12.3)].

Avoid concomitant use of CABLIVI with antiplatelet agents or anticoagulants. Interrupt use of CABLIVI if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.

Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding.
The invention provides a p reparation method for a Flos farfarae active constituent, which comprises the following steps that medicinal materials are extracted through heating, are concentrated, are separated through a silica gel column method and are eluted, eluent is concentrated and is dried, separation is continuously conducted by using a liquid chromatography, and solution is collected, is concentrated and is dried to obtain the active constituent. The Flos farfarae active constituent of the invention can be used as an active ingredient and can be prepared into preparations according to methods recorded in pharmaceutics through adding pharmaceutically acceptable pharmaceutical excipient or carriers. The preparations of the prepared medicines comprise liquid preparations, solid preparations, capsules or pills, and the dosage is oral administration or injection. The Flos farfarae active constituent of the invention can be applied to the preparation of medicines for treating and preventing tumors. The preparation method has the advantages of simple and convenient operation and stable quality. No report on Flos farfarae with activity of fighting against liver tumor exists in the prior art and a research foundation is provided for the research and the development of novel Flos farfarae anti-tumor medicines.
Technical solutions are described for semantic integration of wearable sensors into professional healthcare. One general aspect includes a method that includes receiving, by a communication interface, a disease identifier associated with a patient. The method also includes identifying, by an analysis unit, a measurement identifier based on the disease identifier, where the measurement identifier identifies a health parameter of the patient that is to be monitored. The method also includes receiving, by the communication interface, an anatomy identifier that identifies a body- part of the patient to be used to monitor the health parameter. The method also includes identifying, by a device search unit, a wearable device to monitor the health parameter of the patient at the body-part based on the measurement identifier and the anatomy identifier. Other aspects and examples are also described.
There is provided a method and a system for determining glucose change in a subject, which includes receiving subject model parameters. The subject model parameters of a state-based model of the subject may have been estimated based on: actual glucose measurements and past subject model parameters. An innovation parameter and an innovation covariance parameter are determined using a Kalman filter based on the subject model parameters and a previous state of the subject. A test statistic is calculated based on the determined innovation parameter and the innovation covariance parameter. The calculated test statistic is compared to a given threshold. In response to the calculated test statistic being above the given threshold, an indication of the glucose change is outputted.
There is a need for large-scale production of antibacterials, antioxidants and therapeutic compounds including anti-cancer compounds with low toxicity. The present invention provides processes for the preparation of 3, 5-Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and intermediates used therein. The processes comprise decarboxylation, esterification, cyclization, halogenation and aromatization. In some embodiments the 3, 5-Dihydroxy-4-isopropyl-trans-stilbene is prepared from (E)-2-chloro- 2-isopropyl-5-styrylcyclohexane-l,3-dione. Also disclosed are crystal forms of 3, 5- Dihydroxy-4-isopropyl-trans-stilbene or a salt or solvate thereof and pharmaceutical compositions comprising same. The compounds and processes of the present invention can be manufactured on a larger scale, including with high-yielding synthesis, and have low toxicity.
<P>PROBLEM TO BE SOLVED: To provide sustained release fine particles of a fat-soluble medicine having high enclosure ratio of the fat-soluble medicine, scarcely causing initial burst and not using harmful additive and to provide a method for producing the fine particles.  <P>SOLUTION: The fat-soluble medicine and a biodegradable polymer are dissolved in a fat-soluble vitamin and the solution is jetted into a lecithin thin film and water or a physiological saline is added thereto and then, the fat-soluble vitamin is dispersed into the interior of the thin film by ultrasonic irradiation or homogenizing operation. As a result, globular fine particles in which the fat-soluble vitamin in which the fat-soluble medicine and the biodegradable polymer are dissolved are sealed into the interior of the lecithin thin film are formed. Since strong interaction acts between the lecithin and the fat-soluble vitamin and between the fat-soluble vitamin and the biodegradable polymer, the fat-soluble medicine can be absorbed into the outer surface of fine particles and the enclosure ratio and introduction ratio of the fat-soluble medicine are high. In the production method, stability of the fine particles is also high and the included medicine is scarcely transferred into the blood.  <P>COPYRIGHT: (C)2006,JPO&NCIPI